NovoCure Q4 Earnings Call Highlights

NovoCure (NASDAQ:NVCR) reported grounds fourth-quarter and full-year 2025 gross connected its latest net call, portion outlining regulatory, objective and commercialized milestones expected successful 2026, including the caller FDA support of Optune Pax for locally precocious pancreatic cancer.

Executive Chairman Bill Doyle said 2025 was “a twelvemonth of advancement and change” for the company, highlighted by grounds nett gross of $655 million, up 8% from 2024. The institution besides presented last information from 2 ample randomized trials successful plenary sessions astatine large aesculapian congresses and published the results successful aesculapian journals. During the year, NovoCure submitted premarket support (PMA) applications to the FDA for Tumor Treating Fields (TTFields) therapy successful pancreatic crab and successful encephalon metastases from non-small compartment lung cancer.

→ Hinge Health’s AI Moat Might Be Its Patient Movement Data

Management emphasized that 2026 is expected to beryllium “catalyst-rich,” with aggregate regulatory and objective readouts. Doyle noted the archetypal milestone arrived earlier successful February with FDA support of Optune Pax to dainty locally precocious pancreatic cancer, with regulatory filings submitted successful Europe and Japan. The institution besides expects an FDA determination aboriginal this twelvemonth connected its encephalon metastases PMA.

Doyle said Chief Medical Officer Dr. Nicolas Leupin resigned effectual Feb. 25. Following the departure, NovoCure decided to harvester its technological and objective organizations “to accelerate our R&D execution.” Chief Innovation Officer Dr. Uri Weinberg volition presume the Chief Medical Officer relation successful summation to his existent responsibilities.

→ Microsoft Is Sliding—An Insider Buy and Oversold Signals Are Changing the Setup

CEO Frank Leonard, speaking successful his caller role, said 2025 was the company’s “most palmy commercialized twelvemonth to date” and that absorption expects to transportation momentum into 2026 arsenic NovoCure evolves into a “multi-indication level company.”

Leonard said the company’s glioblastoma (GBM) concern remains core. In 2025, NovoCure saw progressive diligent maturation crossed large markets, driven chiefly extracurricular the U.S. He cited year-over-year progressive diligent maturation of 10% successful Germany, 19% successful France and 29% successful Japan, on with 4% maturation successful the U.S., which helium said had been level successful caller years. For 2026, absorption expects maturation rates to stabilize successful the “low to mid-single digit” scope arsenic markets mature, with humble first-year contributions expected from launches successful Spain, Czechia and British Columbia.